VenoStent, Inc.
                                                                                                                                    
                                                                                                United States
                                                 -                                                 Houston, TX
                                                                                            
                                                                                    - 01/08/2023
 - Series A
 - $16,000,000
 
VenoStent is a venture backed, clinical stage medical device and tissue engineering company that’s developed bioabsorbable polymer scaffolds in order to vastly improve vascular surgery outcomes.
- Industry Medical Device
 - Website https://www.venostent.com/
 - LinkedIn https://www.linkedin.com/company/venostent/
 
Related People
Timothy BoireCo Founder
                                                    
                                                                                                                United States -
                                                         Houston, Texas
                                                    
                                                Highly motivated Biomedical Engineer leveraging strong analytical abilities, communication skills, and leadership qualities to improve the livelihood and wellness of healthcare patients. I have extensive experience with:
- Strategic leadership and management of interdisciplinary teams to achieve organizational, research, and commercialization objectives;
- Identifying knowledge gaps within the healthcare industry through a contemporary understanding of scientific literature, patent searches, market research reports, and customer needs gleaned from interviews with key opinion leaders and other relevant stakeholders;
- Applying this ascertained knowledge within regulatory and business model frameworks to devise and execute a research plan that fosters development of translational healthcare products addressing customer needs;
- Oral presentation of scientific data and product concepts to a diverse range of audiences including investors, physicians, laymen, and scientists with domain-relevant expertise;
- Scientific and non-technical writing;
- Biomaterials, tissue engineering, organic chemistry, material chemistry and characterization, cell culture, protein engineering and purification, vascular engineering, microscopy, image acquisition and analysis, and model development and testing for ex vivo and in vivo systems. 
                                catalyx space |  $5,400,000  | (Nov 4, 2025)
                                Zeeg |  $1,265,935  | (Nov 4, 2025)
                            
                                xMEMS |  $21,000,000  | (Nov 4, 2025)
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                            
                                                
                                                    
                                                    
                                                    
                                                    
                                                    
                                                    
                                                    
                                                
                                                
                                                    
                                                
                                                    
                                                
                                                    
                                                
                                                
                                                
                                                
                                                
                                                                        
                                Cephia AI |  $4,000,000  | (Nov 4, 2025)
                                                                        
                                Ornn |  $5,700,000  | (Nov 4, 2025)
                                                                        
                                octonomy |  $20,000,000  | (Nov 4, 2025)
                                                                        
                                Helex |  $3,500,000  | (Nov 4, 2025)
                                                                        
                                Indomo |  $25,000,000  | (Nov 4, 2025)
                                                                        
                                AUI™ (Augmented Intelligence) |  $20,000,000  | (Nov 4, 2025)
                                                                        
                                Popai Health |  $11,000,000  | (Nov 4, 2025)
                                                                        
                                Mem0 |  $24,000,000  | (Oct 30, 2025)
                                                                        
                                FrontlineIQ |  $3,300,000  | (Oct 30, 2025)